To view this video, please enable marketing cookies from Cookie Preferences in the footer.
In this This Is Why with Dr. Busti pharmacology review, Dr. Busti unpacks the mechanisms, clinical relevance, and evolution of mineralocorticoid receptor antagonists (MRAs) or also referred to as aldosterone antagonists — a class that reshaped the management of heart failure, resistant hypertension, and cirrhosis. From the landmark RALES and EPHESUS trials to the emergence of selective agents like finerenone, he connects the evidence to the underlying physiology, explaining how MRAs influence cardiac remodeling, renal function, and survival outcomes.
Listeners will gain a clear understanding of spironolactone, eplerenone, and finerenone, how structural differences drive their selectivity and side effect profiles, and what to monitor to ensure safe, effective therapy. The goals = pharmacology made relevant and pharmacology made easy
Chapter Table of Contents
00:00:00 Introduction | Understanding MRAs and their clinical evolution
00:01:37 Why MRAs Matter | Mortality benefits in heart failure & hypertension
00:02:28 Drug Class Overview | Spironolactone · Eplerenone · Finerenone
00:03:13 Indications & Uses | Heart failure · CKD · Ascites · Hyperaldosteronism
00:06:27 Clinical Trial Evidence | RALES · EPHESUS · FIDELIO-DKD
00:10:32 Mechanism of Action | Blocking aldosterone & sodium-water retention
00:11:21 Renal Perfusion & Anatomy | How kidney blood flow impacts efficacy
00:15:30 The Nephron in Context | Where MRAs act in the distal nephron
00:39:18 Receptor Selectivity | Steroidal vs nonsteroidal binding differences
00:40:50 Pharmacokinetics | Absorption, distribution & CYP3A4 metabolism
00:42:30 Side Effects | Hyperkalemia, endocrine changes, dose considerations
00:48:20 Structural Chemistry | How design reduces side effects like gynecomastia
00:50:14 Drug Interactions | CYP3A4 inhibitors, ACEi/ARB & NSAID impacts
00:54:41 Monitoring & Labs | Potassium · Renal function · Blood pressure
00:56:40 Patient Counseling | Salt substitutes, polypharmacy & education
00:58:51 Clinical Pearls | Balancing risk and benefit in heart failure care
00:59:38 Closing Thoughts | Evidence meets understanding in MRA therapy
#MRAs #AldosteroneAntagonists #spironolactone #pharmacology #pharmacologymadeeasy
Speaker:
Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education.
Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes.
About This Channel:
This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC).
Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.
More than just access—it’s where understanding deepens.
Create a free account or log in to gain access to this content!
Related Topics
